AZ, Merck get EU nod for Lynparza as adjuvant breast cancer ...
The European Commission has cleared AstraZeneca and Merck & Co's Lynparza as an adjuvant treatment for breast cancer, extending its lead over would-be rivals in the PARP inhibitor class